US Patent No: 5,580,756

Number of patents in Portfolio can not be more than 2000

B7IG fusion protein

1 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C.gamma.1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BRISTOL-MYERS SQUIBB COMPANYPRINCETON, NJ2851

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Brady, William Bothell, WA 47 970
Damle, Nitin K Monmount Junction, NJ 33 916
Ledbetter, Jeffrey A Shoreline, WA 131 2582
Linsley, Peter S Seattle, WA 100 1926

Cited Art Landscape

Patent Info (Count) # Cites Year
 
ROCHE MOLECULAR SYSTEMS, INC. (2)
4,683,202 Process for amplifying nucleic acid sequences 3049 1985
4,683,195 Process for amplifying, detecting, and/or-cloning nucleic acid sequences 2671 1986
 
Genentech, Inc. (1)
5,336,603 CD4 adheson variants 117 1992
 
The Trustees of Columbia University in the City of New York (1)
4,399,216 Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials 441 1980

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
BRISTOL-MYERS SQUIBB COMPANY (19)
6,887,471 Method to inhibit T cell interactions with soluble B7 9 1999
7,094,874 Soluble CTLA4 mutant molecules 19 2001
7,304,033 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 18 2002
7,915,395 Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell 0 2002
7,311,910 Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions 2 2003
7,541,164 Mammalian cell culture processes for protein production 9 2003
7,332,303 Product quality enhancement in mammalian cell culture processes for protein production 16 2003
7,307,064 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 16 2004
7,439,230 Methods of treatment using CTLA4 mutant molecules 6 2004
7,572,772 Soluble CTLA4 mutant molecules 0 2007
7,700,556 Methods of treatment using CTLA4 mutant molecules 3 2007
7,671,022 Methods for treating cardiovascular disease using a soluble CTLA4 molecule 0 2007
7,829,534 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules 1 2007
7,915,222 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis 2 2009
8,227,420 Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID 2 2010
8,148,332 Method for treating a rheumatic disease using a soluble TLA4 molecule 2 2011
8,497,247 Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule 2 2012
8,722,632 Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule 0 2013
8,703,718 Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule 0 2013
 
BIOGEN IDEC INC. (10)
7,175,847 Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 5 2000
6,926,895 Treatment of Crohn's disease using anti-CD80 antibodies that do not inhibit the binding of CD80 antigen to CTLA-4 0 2000
7,192,585 CD80 specific antibodies 8 2005
7,425,447 Host cells expressing 7C10 and 16C10 CD80-specific antibodies 2 2006
7,414,123 Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodies 0 2006
7,417,128 7C10 and 16C10 CD80-specific antibodies 2 2006
7,510,712 Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies 1 2007
7,510,713 Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies 0 2007
7,501,264 Methods of producing 7C10 and 16C10 CD80-specific antibodies 0 2007
7,491,393 Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodies 1 2007
 
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC (7)
7,754,208 Binding domain-immunoglobulin fusion proteins 8 2002
7,829,084 Binding constructs and methods for use thereof 6 2003
8,106,161 Binding domain-immunoglobulin fusion proteins 1 2005
8,333,966 CD37 immunotherapeutics and uses thereof 0 2009
8,147,835 Binding domain-immunoglobulin fusion proteins 1 2009
8,197,810 Binding domain-immunoglobulin fusion proteins 0 2010
8,188,237 Binding domain-immunoglobulin fusion proteins 0 2010
 
AMGEN INC. (6)
7,435,796 Antibodies which bind B7RP1 5 2000
8,624,010 Nucleic acids encoding B7RP1 0 2000
7,153,669 Nucleic acids encoding MK61 receptors 1 2001
7,569,387 Antibody to TNF receptor-like molecules 0 2006
8,470,317 B7RP-1 antagonists 0 2008
8,309,083 Polypeptides involved in immune response 0 2010
 
Genentech, Inc. (6)
7,807,153 Apo-2 receptor agonist antibodies 0 2003
7,750,118 Apo-2 receptor polypeptides 0 2005
7,749,755 Apo-2 receptor polynucleotides 0 2005
7,595,046 Treatment of cancer using anti-Apo-2 antibodies 1 2005
7,939,631 APO-2 receptor polypeptides 0 2010
8,092,799 Antibodies to Apo-2 receptor polypeptides 0 2010
 
GENETICS INSTITUTE, LLC (5)
7,011,833 Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent 3 2000
7,521,532 GL50 polypeptides 5 2002
7,459,544 Nucleic acids encoding B7-2 fusion proteins 0 2003
7,601,813 Anti-GL50 antibodies 5 2005
7,976,840 Use of anti-GL50 antibodies for the downmodulation of an immune response 1 2009
 
Immunex Corporation (4)
7,244,822 BTL-II proteins 0 2003
7,709,618 BTL-II nucleic acids 0 2007
8,173,603 Methods of using BTL-II proteins 0 2010
8,674,078 Methods of using BTL-II proteins 0 2012
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (4)
7,794,710 Methods of enhancing T cell responsiveness 6 2002
7,432,351 B7-H1 variants 11 2003
8,747,833 B7-H1 and methods of diagnosis, prognosis, and treatment of cancer 0 2011
8,460,927 B7-H1 antibodies and method of use 0 2011
 
WYETH (3)
7,029,674 Methods for downmodulating immune cells using an antibody to PD-1 32 2002
8,409,577 Single chain multivalent binding proteins with effector function 0 2007
8,088,905 Nucleic acids encoding antibodies against PD-1 2 2009
 
DANA-FARBER CANCER INSTITUTE, INC. (2)
6,071,716 DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells 13 1993
6,653,444 Polypeptides comprising a B7 extracellular domain 5 1995
 
HESKA CORPORATION (2)
7,053,181 Canine and feline B7-2 proteins, compositions and uses thereof 0 2004
7,385,045 Canine B7-1 nucleic acid molecules 1 2005
 
Human Genome Sciences, Inc. (2)
6,261,801 Nucleic acids encoding tumor necrosis factor receptor 5 2 1998
7,511,017 Methods of treatment with TNFR5 0 2005
 
MAXYGEN, INC. (2)
7,183,376 Variant B7 co-stimulatory molecules 0 2001
7,612,170 Co-stimulatory polypeptides 0 2006
 
ASAHI KASEI KABUSHIKI KAISHA (1)
6,638,741 Differentiation-suppressive polypeptide serrate-2 0 2001
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
6,682,741 .beta.2 microglobulin fusion proteins and high affinity variants 3 2001
 
The United States of America as represented by the Secretary of the Navy (1)
6,685,941 Methods of treating autoimmune disease via CTLA-4Ig 26 1995
 
TRUBION PHARMACEUTICALS (1)
7,754,209 Binding constructs and methods for use thereof 7 2003
 
VALORISATION-RECHERCHE, SOCIETE EN COMMANDITE (1)
7,446,189 Nucleic acids encoding mutant human CD80 and compositions comprising the same 2 2000
 
Other [Check patent profile for assignment information] (2)
8,435,952 Method for retarding progression to definite rheumatoid arthritis in subjects with undifferentiated arthritis 2 2011
8,785,398 Methods of treatment using CTLA4 mutant molecules 0 2011

Full Text

 
loading....